

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM337674

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
BIOThERA, INC.		04/08/2015	CORPORATION: MINNESOTA
LIFE SOURCE BASICS INC.		04/08/2015	CORPORATION: MINNESOTA
BIOThERA HEALTH INC.		04/08/2015	CORPORATION: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	MIDCAP FINANCIAL TRUST, as Agent
<b>Street Address:</b>	7255 Woodmont Avenue, Suite 200
<b>Internal Address:</b>	Attn: Portfolio Management- Life Sciences
<b>City:</b>	Bethesda
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20814
<b>Entity Type:</b>	statutory trust: DELAWARE

## PROPERTY NUMBERS Total: 14

Property Type	Number	Word Mark
Registration Number:	3558118	APG 3-6
Registration Number:	3679778	BETA RIGHT
Registration Number:	3620907	BIOThERA
Registration Number:	4325036	GEM
Serial Number:	85605492	IMMUNE HEALTH BALANCE
Registration Number:	3393014	IMPRIME PGG
Registration Number:	4635237	IMPRIME PGG
Registration Number:	4298761	IMPRIME WGP
Registration Number:	4635238	IMPRIME WGP
Registration Number:	3936384	
Serial Number:	86239967	WELLMUDERM
Registration Number:	3577161	WELLMUNE
Registration Number:	2807439	WGP
Registration Number:	3580966	IMMUNE HEALTH BASICS

## CORRESPONDENCE DATA

TRADEMARK

REEL: 005494 FRAME: 0706

900321125

OP \$365.00 3558118

**Fax Number:** 7036106200

**Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.**

**Phone:** 703-610-6100

**Email:** boxip@hoganlovells.com

**Correspondent Name:** Valerie Brennan, Hogan Lovells US LLP

**Address Line 1:** 7930 Jones Branch Drive, 9th Floor

**Address Line 2:** Box Intellectual Property

**Address Line 4:** McLean, VIRGINIA 22102

<b>NAME OF SUBMITTER:</b>	Valerie Brennan
<b>SIGNATURE:</b>	/vb/
<b>DATE SIGNED:</b>	04/08/2015

**Total Attachments: 27**

source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page1.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page2.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page3.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page4.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page5.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page6.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page7.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page8.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page9.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page10.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page11.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page12.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page13.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page14.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page15.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page16.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page17.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page18.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page19.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page20.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page21.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page22.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page23.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page24.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page25.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page26.tif  
source=Biothera to MidCap EXECUTED IP Security Agreement formatted#page27.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the 8th day of April, 2015 by and between MIDCAP FINANCIAL TRUST, a Delaware statutory trust ("**Agent**"), BIOTHERA, INC., a Minnesota corporation ("**Biothera**"), LIFE SOURCE BASICS INC., a Minnesota corporation ("**Life Source**") and BIOTHERA HEALTH INC., a Delaware corporation ("**Biothera Health**" and, collectively, with Biothera and Life Source, in the singular, "**Grantor**").

### RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "**Credit Extensions**") in the amounts and manner set forth in that certain Credit and Security Agreement by and between Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "**Credit Agreement**"; capitalized terms used herein are used as defined in the Credit Agreement). The Lenders are willing to make the Credit Extensions to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Credit Agreement, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "**Intellectual Property Collateral**"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "**Copyrights**");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the

same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "**Patents**");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto, but excluding all intent-to-use trademarks (collectively, the "**Trademarks**");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "**Mask Works**");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

[Signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:


Address of Grantor:

BIOTHERA, INC., a Minnesota corporation


Biothera  
3388 Mike Collins Drive  
Eagan, Minnesota, 55121  
Attention: Richard Mueller  
Fax: 651-675-0400  
E-Mail:

By:   
Name: Richard Mueller  
Title: Chief Executive Officer

LIFE SOURCE BASICS INC., a Minnesota corporation

By:   
Name: Richard Mueller  
Title: President

BIOTHERA HEALTH INC., a Delaware corporation

By:   
Name: Richard Mueller  
Title: President

AGENT:

Address of Agent:

MIDCAP FINANCIAL TRUST, a  
Delaware statutory trust

c/o MidCap Financial Services, LLC,  
as servicer  
7255 Woodmont Avenue, Suite 200  
Bethesda, Maryland 20814  
Attn: Portfolio Management- Life Sciences

By: Apollo Capital Management, L.P., its  
investment manager

By: Apollo Capital Management GP, LLC, its  
general partner


By:  (SEAL)  
Name: Maurice Amsellem  
Title: Authorized Signatory

EXHIBIT A

Copyrights

<b>Copyright</b>	<b>Owner</b>	<b>Registration Number</b>	<b>Filing Date</b>
Wellmune text and symbol	Biothera, Inc.	VAu000752821	8/01/07

EXHIBIT B

Patents

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
1.	Biothera Inc.	USES FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN AND COMPOSITIONS COMPRISING SAME	United States	5,783,569	1/26/1995	Granted
	Biothera Inc.	UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN, COMPOSITION AND METHOD OF MAKING THE SAME	United States	5,817,643	6/6/1995	Granted
2.	Biothera Inc.	METHOD FOR PRODUCING SOLUBLE GLUCANS	United States	5,811,542	5/2/1995	Granted
3.	Biothera Inc.	ENHANCEMENT OF NON-SPECIFIC IMMUNE DEFENSES BY ADMINISTRATION OF UNDERIVATIZED, AQUEOUS SOLUBLE GLUCANS	United States	5,849,720	3/8/1995	Granted
4.	Biothera Inc.	CONFORMATIONS OF PPG-GLUCAN	United States	6,046,323	7/29/1997	Granted
5.	Biothera Inc.	$\beta(1-3)$ - GLUCAN DIAGNOSTIC ASSAYS	United States	6,084,092	12/12/1997	Granted
	Biothera Inc.	$\beta(1-3)$ - GLUCAN DIAGNOSTIC ASSAYS	United States	6,294,321	1/27/2000	Granted
	Biothera Inc.	$\beta(1,3)$ -GLUCAN DIAGNOSTIC ASSAYS	United States	6,413,715	6/19/2001	Granted



Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Biothera Inc.	$\beta$ (1-3) - GLUCAN DIAGNOSTIC ASSAYS	Australia	718650 (WO199903 1510A1)	5/1/1997	Granted
<b>6.</b>	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	United States	6,110,692	1/31/1997	Granted
	Biothera Inc.	ASSAY FOR BINDING BETWEEN CARBOHYDRATE AND GLYCOLIPID	United States	6,630,310	10/30/1998	Granted
	Biothera Inc.	ACTIVATION OF SIGNAL TRANSDUCTION BY UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	United States	6,090,938	6/14/1996	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	Japan	3920349 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	South Korea	561660 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	Austria	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	Belgium	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	France	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta$ (1,3) GLUCAN	Germany	900379	5/1/1997	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Inc.	AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN		(WO199704 1439A1)		
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Italy	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Netherlands	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Spain	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Switzerland	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	United Kingdom	900379 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Canada	2253257 (WO199704 1439A1)	5/1/1997	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Mexico	314672 (WO200001 3019A1)	8/19/1999	Granted
	Biothera Inc.	RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $\beta(1,3)$ GLUCAN	Australia	749716 (WO200001 3019A1)	8/19/1999	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
8.	Biothera Inc.	MOBILIZATION OF PERIPHERAL BLOOD PRECURSOR CELLS BY $\beta$ (1,3)-GLUCAN	United States	6,117,850	5/9/1996	Granted
9.	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	United States	6,355,625	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Canada	2344166 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Mexico	262444 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Austria	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Belgium	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Switzerland	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Cyprus	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Germany	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Denmark	1 121 135	9/14/1998	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Inc.	SPECIFIC IVIG		(EP 1121135)		
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Spain	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Finland	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	France	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Greece	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Ireland	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Italy	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Luxembourg	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Monaco	1 121 135 (EP 1121135)	9/14/1998	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Netherlands	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Portugal	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	Sweden	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	United Kingdom	1 121 135 (EP 1121135)	9/14/1998	Granted
	Biothera Inc.	COMPOSITIONS OF $\beta$ -GLUCAN AND SPECIFIC IVIG	United States	7,030,101	9/14/1998	Granted
<b>10.</b>	Biothera Inc.	VERY HIGH MOLECULAR WEIGHT $\beta$ -GLUCANS	United States	6,369,216	4/9/2002	Granted
	Biothera Inc.	VERY HIGH MOLECULAR WEIGHT $\beta$ -GLUCANS	United States	7,022,685	4/4/2006	Granted
	Biothera Inc.	VERY HIGH MOLECULAR WEIGHT $\beta$ -GLUCANS	United States	7,566,704	7/28/2009	Granted
<b>11.</b>	Biothera Inc.	USE OF BETA-GLUCANS AGAINST BIOLOGICAL WARFARE WEAPONS AND PATHOGENS INCLUDING ANTHRAX	United States	7,786,094	10/9/2002	Granted
	Biothera Inc.	USE OF BETA-GLUCANS AGAINST BIOLOGICAL WARFARE WEAPONS	China	ZL2003801 05493.5	10/9/2002	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
		AND PATHOGENS INCLUDING ANTHRAX				
	Biothera Inc.	USE OF BETA-GLUCANS AGAINST BIOLOGICAL WARFARE WEAPONS AND PATHOGENS INCLUDING ANTHRAX	United States	8,865,679	8/30/2010	Granted
<b>12.</b>	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	7,981,447	5/8/2008	Granted
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	8,530,642	7/11/2011	Granted
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	8,859,759	4/24/2013	Granted
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Australia	2008251847 (WO200814 0744A1)	5/8/2008	Granted
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Brazil	PI 0811274-6 (WO200814 0744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Canada	2690918 (WO200814 0744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	China	2008800149 57.4 (WO200814 0744A1)	5/8/2008	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Colombia	9138987 (WO2008140744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Europe	8754267.6 (WO2008140744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Indonesia	W- 0020090345 3 (WO2008140744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Japan	2010- 507462 (WO2008140744A1)	5/8/2008	Granted
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Japan	2014- 120772 (WO2008140744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	South Korea	10-2009- 7025513 (WO2008140744A1)	5/8/2008	Pending
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Mexico	294026 (WO2008140744A1)	5/9/2008	Granted
	Biothera	PARTICULATE-SOLUBLE GLUCAN	Mexico	MX/a/2010/	5/9/2008	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Inc.	PREPARATION		008055 (WO200814 0744A1)		
	Biothera Inc.	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Malaysia	PI 20094702 (WO200814 0744A1)	5/8/2008	Granted
	Biothera Inc.	PROCESS FOR PRODUCING A SOLUBLE $\beta$ -GLUCAN	Ukraine	101617 (WO200814 0744A1)	5/8/2008	Granted
<b>14.</b>	Biothera Inc.	GLUCAN PREPARATIONS	United States	11/818,741 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Mexico	297088 (WO200714 6416A2)	6/15/2007	Granted
	Biothera Inc.	GLUCAN PREPARATIONS	Australia	2007258191 (WO200714 6416A2)	6/15/2007	Granted
	Biothera Inc.	GLUCAN PREPARATIONS	Australia	2014201427 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Brazil	PI 0713734- 6 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Canada	2,655,414 (WO200714)	6/15/2007	Pending



Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
				6416A2)		
	Biothera Inc.	GLUCAN PREPARATIONS	China	2007800299 44.X (WO200714 6416A2)	6/15/2007	Granted
	Biothera Inc.	GLUCAN PREPARATIONS	Europe	07796157.1 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Hong Kong	10103440.8 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Israel	195937 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Japan	2009- 515512 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Japan	2013- 228688 (WO200714 6416A2)	6/15/2007	Pending
	Biothera Inc.	GLUCAN PREPARATIONS	Russia	2009101051 (WO200714 6416A2)	6/15/2007	Granted
	Biothera Inc.	GLUCAN PREPARATIONS	Singapore	200809231- 4	6/15/2007	Granted

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
				(WO200714 6416A2)		
	Biothera Inc.	GLUCAN PREPARATIONS	Singapore	201005698- 4 (WO200714 6416A2)	6/15/2007	Pending
15.	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	United States	12/286,185 (WO200904 2230A1)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Australia	2008305545 (WO200904 2230)	9/29/2008	Granted
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Canada	2700922 (WO200904 2230)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	China	2008801177 33.6 (WO200904 2230)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	China	ZL2011102 25696.4 (WO200904 2230)	9/29/2008	Granted
	Biothera	THE USE OF $\beta$ -GLUCAN ON UPPER	Europe	8833584.9	9/29/2008	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Inc.	RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING		(WO200904 2230)		
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Hong Kong	12106829.0 (WO200904 2230)	9/29/2008	Granted
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Japan	2010-526967 (WO200904 2230)	9/29/2008	Granted
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	South Korea	10-2010-7009071 (WO200904 2230)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Mexico	MX/a/2010/003462 (WO200904 2230)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Malaysia	PI 2010001341 (WO200904 2230)	9/29/2008	Pending
	Biothera Inc.	THE USE OF $\beta$ -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Philippines	10-2010-500664 (WO200904 2230)	9/29/2008	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
18.	Biothera Inc.	MODIFIED AND DERIVATIZED B-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS	United States	14/115,824 (WO2012154680A2)	5/7/2012	Pending
19.	Biothera Inc.	$\beta$ -GLUCAN COMPOUNDS, COMPOSITIONS AND METHODS	United States	14/116,550 (WO2012154818A1)	5/9/2012	Pending
20.	Biothera Inc.	OPSONIZED B-GLUCAN PREPARATIONS AND METHODS	United States	14/123,624 (WO2012167061A1)	6/1/2012	Pending
	Biothera Inc.	OPSONIZED B-GLUCAN PREPARATIONS AND METHODS	Europe	12793220 (WO2012167061A1)	6/1/2012	Pending
21.	Biothera Inc.	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	United States	14/343,655 (WO2013036712A1)	9/9/2011	Pending
	Biothera Inc.	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	Europe	12829310.7 (WO2013036712A1)	9/9/2011	Pending
22.	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	United States	14/398,019 (WO2013195591A1)	10/30/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	Europe	13784589.7 (WO2013195591A1)	11/18/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	Japan	Unknown (WO2013195591A1)	10/30/2014	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
				5591A1)		
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	Canada	2,872,009 (WO201319 5591A1)	10/29/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	Australia	2013257139 (WO201319 5591A1)	11/5/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	China	0138003497 8.3 (WO201319 5591A)	12/30/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	South Korea	2014-7033316 (WO201319 5591A1)	11/26/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	Russia	2014148153 (WO201319 5591A1)	11/28/2014	Pending
	Biothera Inc.	$\beta$ -GLUCAN IMMUNOTHERAPEUTIC METHODS	India	Unknown (WO201319 5591A1)	11/25/2014	Pending
23.	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	United States	14/398,020 (WO201316 5593A1)	10/30/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Europe	13784472.6 (WO201316 5593A1)	11/28/2014	Pending

Group Number	Owner	Title	Country	Patent/ Application Number	Filing date	Status
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Japan	Unknown (WO201316 5593A1)	10/30/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Canada	2,872,010 (WO201316 5593A1)	10/29/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Australia	2013257141 (WO201316 5593A1)	11/6/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	China	2013800349 80.0 (WO201316 5593A1)	12/30/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	South Korea	2014-7033313 (WO201316 5593A1)	11/26/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Russia	2014148155 (WO201316 5593A1)	11/28/2014	Pending
	Biothera Inc.	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	India	Unknown (WO201316 5593A1)	11/25/2014	Pending
25.	Biothera Inc.	PROCESS FOR REDUCING OFF-FLAVOR PRODUCTION OF GLUCAN	United States	PCT/US201 4/63881	11/4/2014	Pending

EXHIBIT C

Trademarks

<b>Trademark</b>	<b>Owner</b>	<b>Country</b>	<b>Status</b>	<b>Registration Number</b>
(WELLMUNE Korean Transliteration)	Biothera, Inc.	Korea, Republic of	Registered	400968167
APG 3-6 & Design (Color) (1)	Biothera, Inc.	China (People's Republic)	Registered	5939435
APG 3-6 & Design (Color) (1)	Biothera, Inc.	European Community	Registered	005690912
APG 3-6 & Design (Color) (1)	Biothera, Inc.	Korea, Republic of	Registered	733204
APG 3-6 & Design (Color) (1)	Biothera, Inc.	United States of America	Registered	3,558,118
BETA RIGHT	Biothera, Inc.	Canada	Registered	TMA682010
BETA RIGHT	Biothera, Inc.	China (People's Republic)	Registered	3916980
BETA RIGHT	Biothera, Inc.	European Community	Registered	3642981
BETA RIGHT	Biothera, Inc.	Japan	Registered	5155614
BETA RIGHT	Biothera, Inc.	United States of America	Registered	3,679,778
BETARIGHT	Biothera, Inc.	Taiwan	Registered	1152988
BIOTHERA	Biothera, Inc.	Canada	Registered	TMA859253
BIOTHERA	Biothera, Inc.	United States of America	Registered	3,620,907
GEM	Biothera, Inc.	United States of America	Registered	4,325,036
IMMUNE HEALTH BALANCE	Biothera, Inc.	Canada	Pending	
Immune Health Balance	Biothera, Inc.	United States of America	Published	
IMMUNE HEALTH BASICS	Biothera, Inc.	United States of America	Registered	3,580,966
IMMUNOFIBER	Biothera, Inc.	Japan	Registered	5009329

IMPRIME PGG	Biothera, Inc.	United States of America	Registered	3,393,014
IMPRIME PGG	Biothera, Inc.	United States of America	Registered	4,635,237
IMPRIME WGP	Biothera, Inc.	United States of America	Registered	4,298,761
IMPRIME WGP	Biothera, Inc.	United States of America	Registered	4,635,238
IMUCELL	Biothera, Inc.	Canada	Registered	TMA647684
IMUCELL	Biothera, Inc.	China (People's Republic)	Registered	10036002
IMUCELL	Biothera, Inc.	Japan	Registered	5181311
IMUCELL WGP	Biothera, Inc.	Philippines	Registered	4200500146
LIFE SOURCE BASICS	Biothera, Inc.	China (People's Republic)	Pending	
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Australia	Registered	1348550
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Canada	Registered	TM828823
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	China (People's Republic)	Registered	1029234
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	European Community	Registered	008859654
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	Hong Kong	Registered	301539414
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	Indonesia	Pending	
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Korea, Republic of	Registered	1029234
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	Malaysia	Registered	2010002204
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	Mexico	Registered	1198655



icon)				
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	New Zealand	Registered	819223
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Norway	Registered	1029234
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Russian Federation	Registered	1029234
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Singapore	Registered	T1002716Z
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	South Africa	Registered	201002525
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Switzerland	Registered	1029234
Miscellaneous Design (1) (dotted icon)	Biothera, Inc.	Taiwan	Registered	1436116
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Turkey	Registered	1029234
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Ukraine	Registered	1029234
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	United States of America	Registered	3,936,384
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Venezuela	Published	
Miscellaneous Design (1) (Dotted Icon)	Biothera, Inc.	Vietnam	Registered	1029234
Opposition of Bio-Thera & Device (10390049)	Biothera, Inc.	China (People's Republic)	Pending	
Opposition of Bio-Thera & Device (10390150)	Biothera, Inc.	China (People's Republic)	Pending	

WELLMUDERM	Biothera, Inc.	Canada	Pending	
WELLMUDERM	Biothera, Inc.	European Community	Registered	8972499
WELLMUDERM	Biothera, Inc.	United States of America	Pending	
WELLMUNE	Biothera, Inc.	Argentina	Registered	2240568
WELLMUNE	Biothera, Inc.	Australia	Registered	1190068
WELLMUNE	Biothera, Inc.	Brazil	Registered	829282386
WELLMUNE	Biothera, Inc.	Canada	Registered	TMA756726
WELLMUNE	Biothera, Inc.	Chile	Registered	810948
WELLMUNE	Biothera, Inc.	China (People's Republic)	Registered	6258961
WELLMUNE	Biothera, Inc.	Colombia	Registered	352919
WELLMUNE	Biothera, Inc.	Croatia	Registered	Z20071453
WELLMUNE	Biothera, Inc.	European Community	Registered	006164388
WELLMUNE	Biothera, Inc.	Hong Kong	Registered	300920402
WELLMUNE	Biothera, Inc.	India	Registered	1584078
WELLMUNE	Biothera, Inc.	Indonesia	Pending	
WELLMUNE	Biothera, Inc.	Japan	Registered	5107622
WELLMUNE	Biothera, Inc.	Korea, Republic of	Registered	400762099
WELLMUNE	Biothera, Inc.	Malaysia	Registered	07014943
WELLMUNE	Biothera, Inc.	Mexico	Registered	1030693
WELLMUNE	Biothera, Inc.	New Zealand	Registered	810636
WELLMUNE	Biothera, Inc.	Nigeria	Opposed	
WELLMUNE	Biothera, Inc.	Norway	Registered	243218
WELLMUNE	Biothera, Inc.	Russian Federation	Registered	366227
WELLMUNE	Biothera, Inc.	Singapore	Registered	T0911966H
WELLMUNE	Biothera, Inc.	South Africa	Registered	200717274
WELLMUNE	Biothera, Inc.	Switzerland	Registered	564670
WELLMUNE	Biothera, Inc.	Taiwan	Registered	1334465

WELLMUNE	Biothera, Inc.	Thailand	Registered	TM283319
WELLMUNE	Biothera, Inc.	Turkey	Registered	200751514
WELLMUNE	Biothera, Inc.	Ukraine	Registered	101768
WELLMUNE	Biothera, Inc.	United States of America	Registered	3,577,161
WELLMUNE	Biothera, Inc.	Venezuela	Published	
WELLMUNE	Biothera, Inc.	Vietnam	Registered	105164
WELLMUNE (Chinese characters)	Biothera, Inc.	China (People's Republic)	Registered	6918055
WELLMUNE (Chinese characters)	Biothera, Inc.	Hong Kong	Registered	301184373
WELLMUNE (Chinese characters)	Biothera, Inc.	Taiwan	Registered	1377279
WELLMUNE (Hindi characters)	Biothera, Inc.	India	Registered	966560
WELLMUNE (Japanese characters)	Biothera, Inc.	Japan	Registered	5215454
WELLMUNE (Russian characters)	Biothera, Inc.	Russian Federation	Registered	413485
WGP	Biothera, Inc.	Canada	Registered	TMA682011
WGP	Biothera, Inc.	China (People's Republic)	Registered	3916981
WGP	Biothera, Inc.	European Community	Registered	2727501
WGP	Biothera, Inc.	Japan	Registered	4713571
WGP	Biothera, Inc.	Japan	Registered	4960101
WGP	Biothera, Inc.	Taiwan	Registered	1152987
WGP	Biothera, Inc.	United States of America	Registered	2,807,439
WGP 3-6	Biothera, Inc.	Korea, Republic of	Registered	400732399
WGP 3-6	Biothera, Inc.	Singapore	Registered	T0627999J

WGP 3-6	Biothera, Inc.	Singapore	Registered	T0628000Z
---------	----------------	-----------	------------	-----------

EXHIBIT D

Mask Works

None.